What is Medra?
Medra is building the world's first end-to-end Physical AI Scientist platform designed for continuous experimentation. The company operates at the intersection of robotics, machine learning, and life sciences, providing a comprehensive solution that manages the entire drug discovery pipeline. Unlike traditional research models that rely on fragmented, manual processes, Medra's platform utilizes real-time optimization to predict therapeutic success across every stage of development. By bridging the gap between digital intelligence and physical laboratory execution, Medra is establishing a new paradigm for biotech innovation, enabling researchers to iterate faster and with greater precision than previously possible.
How much funding has Medra raised?
Medra has raised a total of $52M across 1 funding round:
Series A
$52M
Series A (2025): $52M with participation from Human Capital, Neo, Catalio Capital Management, Menlo Ventures, and Seven Seven Six
Key Investors in Medra
Human Capital
Human Capital is a venture firm that invests in and helps build engineering teams for engineering-centric startups, managing over $1.4 billion in assets.
Catalio Capital Management
Catalio Capital Management is a New York-based firm specializing in innovative healthcare investing across private, public, and credit markets with a focus on breakthrough biomedical technology.
Menlo Ventures
Menlo Ventures is a Menlo Park-based venture capital firm that invests in early and growth-stage technology companies across sectors such as enterprise software and frontier tech.
What's next for Medra?
With this major strategic investment, Medra is poised to expand its operational footprint and enhance its robotic infrastructure. The company plans to leverage the new capital to deepen its R&D capabilities, focusing on the integration of more complex biological assays into its automated platform. As the firm scales, it will likely prioritize strategic partnerships with major pharmaceutical entities looking to modernize their discovery pipelines. The focus remains on achieving a scalable, predictive model that can handle the high-throughput demands of modern drug development, ultimately aiming to shorten the timeline from initial hypothesis to clinical trial readiness.
See full Medra company page
